nodes	percent_of_prediction	percent_of_DWPC	metapath
Indacaterol—ABCB1—Mitoxantrone—lymphatic system cancer	0.143	0.207	CbGbCtD
Indacaterol—CYP3A4—Cytarabine—lymphatic system cancer	0.125	0.18	CbGbCtD
Indacaterol—CYP3A4—Teniposide—lymphatic system cancer	0.123	0.177	CbGbCtD
Indacaterol—ABCB1—Vincristine—lymphatic system cancer	0.0986	0.142	CbGbCtD
Indacaterol—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0858	0.124	CbGbCtD
Indacaterol—ABCB1—Methotrexate—lymphatic system cancer	0.0597	0.086	CbGbCtD
Indacaterol—CYP3A4—Vincristine—lymphatic system cancer	0.0591	0.0851	CbGbCtD
Indacaterol—Chronic obstructive pulmonary disease—Methotrexate—lymphatic system cancer	0.00795	0.026	CcSEcCtD
Indacaterol—Myocardial ischaemia—Mitoxantrone—lymphatic system cancer	0.00567	0.0185	CcSEcCtD
Indacaterol—Bronchospasm—Teniposide—lymphatic system cancer	0.00538	0.0176	CcSEcCtD
Indacaterol—Musculoskeletal pain—Vincristine—lymphatic system cancer	0.00474	0.0155	CcSEcCtD
Indacaterol—Angina pectoris—Fludarabine—lymphatic system cancer	0.00468	0.0153	CcSEcCtD
Indacaterol—Vertigo—Mechlorethamine—lymphatic system cancer	0.00464	0.0152	CcSEcCtD
Indacaterol—Upper respiratory tract infection—Fludarabine—lymphatic system cancer	0.00447	0.0146	CcSEcCtD
Indacaterol—Unspecified disorder of skin and subcutaneous tissue—Mechlorethamine—lymphatic system cancer	0.00437	0.0143	CcSEcCtD
Indacaterol—Hyperglycaemia—Fludarabine—lymphatic system cancer	0.00434	0.0142	CcSEcCtD
Indacaterol—Pneumonia—Fludarabine—lymphatic system cancer	0.00431	0.0141	CcSEcCtD
Indacaterol—Infection—Mechlorethamine—lymphatic system cancer	0.00419	0.0137	CcSEcCtD
Indacaterol—Skin disorder—Mechlorethamine—lymphatic system cancer	0.0041	0.0134	CcSEcCtD
Indacaterol—Diabetes mellitus—Carmustine—lymphatic system cancer	0.00409	0.0134	CcSEcCtD
Indacaterol—Sinusitis—Fludarabine—lymphatic system cancer	0.00402	0.0131	CcSEcCtD
Indacaterol—Anaemia—Teniposide—lymphatic system cancer	0.00352	0.0115	CcSEcCtD
Indacaterol—Bronchospasm—Bleomycin—lymphatic system cancer	0.00347	0.0113	CcSEcCtD
Indacaterol—Malnutrition—Fludarabine—lymphatic system cancer	0.00335	0.0109	CcSEcCtD
Indacaterol—Chest pain—Teniposide—lymphatic system cancer	0.00324	0.0106	CcSEcCtD
Indacaterol—Hypokalaemia—Carmustine—lymphatic system cancer	0.00324	0.0106	CcSEcCtD
Indacaterol—Pneumonia—Bleomycin—lymphatic system cancer	0.00316	0.0103	CcSEcCtD
Indacaterol—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.00311	0.0101	CcSEcCtD
Indacaterol—Anaemia—Fludarabine—lymphatic system cancer	0.0031	0.0101	CcSEcCtD
Indacaterol—Infection—Teniposide—lymphatic system cancer	0.00309	0.0101	CcSEcCtD
Indacaterol—Tachycardia—Teniposide—lymphatic system cancer	0.00304	0.00991	CcSEcCtD
Indacaterol—Hypokalaemia—Mitoxantrone—lymphatic system cancer	0.00301	0.00983	CcSEcCtD
Indacaterol—Pruritus—Mechlorethamine—lymphatic system cancer	0.00298	0.00975	CcSEcCtD
Indacaterol—Cough—Fludarabine—lymphatic system cancer	0.00292	0.00954	CcSEcCtD
Indacaterol—Myalgia—Fludarabine—lymphatic system cancer	0.00285	0.00931	CcSEcCtD
Indacaterol—Hyperglycaemia—Carmustine—lymphatic system cancer	0.00278	0.00906	CcSEcCtD
Indacaterol—Dyspnoea—Teniposide—lymphatic system cancer	0.00277	0.00905	CcSEcCtD
Indacaterol—Pneumonia—Carmustine—lymphatic system cancer	0.00276	0.00901	CcSEcCtD
Indacaterol—Infection—Fludarabine—lymphatic system cancer	0.00272	0.00887	CcSEcCtD
Indacaterol—Nervous system disorder—Fludarabine—lymphatic system cancer	0.00268	0.00875	CcSEcCtD
Indacaterol—Rash—Mechlorethamine—lymphatic system cancer	0.00266	0.00869	CcSEcCtD
Indacaterol—Upper respiratory tract infection—Mitoxantrone—lymphatic system cancer	0.00266	0.00868	CcSEcCtD
Indacaterol—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00266	0.00868	CcSEcCtD
Indacaterol—Pneumonia—Vincristine—lymphatic system cancer	0.00263	0.0086	CcSEcCtD
Indacaterol—Hyperglycaemia—Mitoxantrone—lymphatic system cancer	0.00258	0.00842	CcSEcCtD
Indacaterol—Pneumonia—Mitoxantrone—lymphatic system cancer	0.00256	0.00838	CcSEcCtD
Indacaterol—Nausea—Mechlorethamine—lymphatic system cancer	0.00251	0.00818	CcSEcCtD
Indacaterol—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.00249	0.00813	CcSEcCtD
Indacaterol—Paraesthesia—Fludarabine—lymphatic system cancer	0.00245	0.00802	CcSEcCtD
Indacaterol—Dyspnoea—Fludarabine—lymphatic system cancer	0.00244	0.00796	CcSEcCtD
Indacaterol—Oedema peripheral—Carmustine—lymphatic system cancer	0.00243	0.00792	CcSEcCtD
Indacaterol—Connective tissue disorder—Carmustine—lymphatic system cancer	0.00242	0.0079	CcSEcCtD
Indacaterol—Sinusitis—Mitoxantrone—lymphatic system cancer	0.00239	0.00781	CcSEcCtD
Indacaterol—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00236	0.00771	CcSEcCtD
Indacaterol—Connective tissue disorder—Vincristine—lymphatic system cancer	0.00231	0.00754	CcSEcCtD
Indacaterol—Hypersensitivity—Teniposide—lymphatic system cancer	0.00229	0.00748	CcSEcCtD
Indacaterol—Anaemia—Bleomycin—lymphatic system cancer	0.00227	0.00741	CcSEcCtD
Indacaterol—Pruritus—Teniposide—lymphatic system cancer	0.0022	0.00719	CcSEcCtD
Indacaterol—Cardiac disorder—Vincristine—lymphatic system cancer	0.00218	0.00712	CcSEcCtD
Indacaterol—Malnutrition—Carmustine—lymphatic system cancer	0.00214	0.007	CcSEcCtD
Indacaterol—Cough—Bleomycin—lymphatic system cancer	0.00214	0.007	CcSEcCtD
Indacaterol—Mediastinal disorder—Vincristine—lymphatic system cancer	0.00212	0.00692	CcSEcCtD
Indacaterol—Chest pain—Bleomycin—lymphatic system cancer	0.00209	0.00683	CcSEcCtD
Indacaterol—Myalgia—Bleomycin—lymphatic system cancer	0.00209	0.00683	CcSEcCtD
Indacaterol—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00201	0.00658	CcSEcCtD
Indacaterol—Tremor—Carmustine—lymphatic system cancer	0.00201	0.00656	CcSEcCtD
Indacaterol—Infection—Bleomycin—lymphatic system cancer	0.00199	0.0065	CcSEcCtD
Indacaterol—Anaemia—Carmustine—lymphatic system cancer	0.00198	0.00647	CcSEcCtD
Indacaterol—Rash—Teniposide—lymphatic system cancer	0.00196	0.0064	CcSEcCtD
Indacaterol—Dermatitis—Teniposide—lymphatic system cancer	0.00196	0.0064	CcSEcCtD
Indacaterol—Headache—Teniposide—lymphatic system cancer	0.00195	0.00636	CcSEcCtD
Indacaterol—Pruritus—Fludarabine—lymphatic system cancer	0.00193	0.00632	CcSEcCtD
Indacaterol—Diabetes mellitus—Methotrexate—lymphatic system cancer	0.0019	0.00619	CcSEcCtD
Indacaterol—Anaemia—Vincristine—lymphatic system cancer	0.00189	0.00618	CcSEcCtD
Indacaterol—Nausea—Teniposide—lymphatic system cancer	0.00185	0.00603	CcSEcCtD
Indacaterol—Anaemia—Mitoxantrone—lymphatic system cancer	0.00184	0.00601	CcSEcCtD
Indacaterol—Vertigo—Vincristine—lymphatic system cancer	0.00184	0.006	CcSEcCtD
Indacaterol—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00183	0.00596	CcSEcCtD
Indacaterol—Chest pain—Carmustine—lymphatic system cancer	0.00182	0.00596	CcSEcCtD
Indacaterol—Myalgia—Carmustine—lymphatic system cancer	0.00182	0.00596	CcSEcCtD
Indacaterol—Paraesthesia—Bleomycin—lymphatic system cancer	0.0018	0.00588	CcSEcCtD
Indacaterol—Dyspnoea—Bleomycin—lymphatic system cancer	0.00179	0.00583	CcSEcCtD
Indacaterol—Myalgia—Vincristine—lymphatic system cancer	0.00174	0.00569	CcSEcCtD
Indacaterol—Cough—Mitoxantrone—lymphatic system cancer	0.00174	0.00568	CcSEcCtD
Indacaterol—Infection—Carmustine—lymphatic system cancer	0.00174	0.00568	CcSEcCtD
Indacaterol—Rash—Fludarabine—lymphatic system cancer	0.00172	0.00563	CcSEcCtD
Indacaterol—Dermatitis—Fludarabine—lymphatic system cancer	0.00172	0.00562	CcSEcCtD
Indacaterol—Headache—Fludarabine—lymphatic system cancer	0.00171	0.00559	CcSEcCtD
Indacaterol—Tachycardia—Carmustine—lymphatic system cancer	0.00171	0.00558	CcSEcCtD
Indacaterol—Myalgia—Mitoxantrone—lymphatic system cancer	0.0017	0.00554	CcSEcCtD
Indacaterol—Chest pain—Mitoxantrone—lymphatic system cancer	0.0017	0.00554	CcSEcCtD
Indacaterol—Infection—Vincristine—lymphatic system cancer	0.00166	0.00542	CcSEcCtD
Indacaterol—Nervous system disorder—Vincristine—lymphatic system cancer	0.00164	0.00535	CcSEcCtD
Indacaterol—Nausea—Fludarabine—lymphatic system cancer	0.00162	0.0053	CcSEcCtD
Indacaterol—Infection—Mitoxantrone—lymphatic system cancer	0.00162	0.00528	CcSEcCtD
Indacaterol—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00159	0.0052	CcSEcCtD
Indacaterol—Tachycardia—Mitoxantrone—lymphatic system cancer	0.00159	0.00518	CcSEcCtD
Indacaterol—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00158	0.00516	CcSEcCtD
Indacaterol—Paraesthesia—Carmustine—lymphatic system cancer	0.00157	0.00513	CcSEcCtD
Indacaterol—Dyspnoea—Carmustine—lymphatic system cancer	0.00156	0.00509	CcSEcCtD
Indacaterol—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00152	0.00497	CcSEcCtD
Indacaterol—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00151	0.00493	CcSEcCtD
Indacaterol—Paraesthesia—Vincristine—lymphatic system cancer	0.0015	0.0049	CcSEcCtD
Indacaterol—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00148	0.00484	CcSEcCtD
Indacaterol—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00148	0.00482	CcSEcCtD
Indacaterol—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.00146	0.00477	CcSEcCtD
Indacaterol—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00145	0.00473	CcSEcCtD
Indacaterol—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00144	0.00471	CcSEcCtD
Indacaterol—Asthma—Methotrexate—lymphatic system cancer	0.00142	0.00465	CcSEcCtD
Indacaterol—Pruritus—Bleomycin—lymphatic system cancer	0.00142	0.00463	CcSEcCtD
Indacaterol—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.00132	0.00432	CcSEcCtD
Indacaterol—Hypersensitivity—Carmustine—lymphatic system cancer	0.00129	0.00421	CcSEcCtD
Indacaterol—Pneumonia—Methotrexate—lymphatic system cancer	0.00128	0.00417	CcSEcCtD
Indacaterol—Infestation—Methotrexate—lymphatic system cancer	0.00127	0.00415	CcSEcCtD
Indacaterol—Infestation NOS—Methotrexate—lymphatic system cancer	0.00127	0.00415	CcSEcCtD
Indacaterol—Rash—Bleomycin—lymphatic system cancer	0.00126	0.00413	CcSEcCtD
Indacaterol—Dermatitis—Bleomycin—lymphatic system cancer	0.00126	0.00412	CcSEcCtD
Indacaterol—Hypersensitivity—Vincristine—lymphatic system cancer	0.00123	0.00402	CcSEcCtD
Indacaterol—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.0012	0.00391	CcSEcCtD
Indacaterol—Nausea—Bleomycin—lymphatic system cancer	0.00119	0.00389	CcSEcCtD
Indacaterol—Dizziness—Carmustine—lymphatic system cancer	0.00116	0.00378	CcSEcCtD
Indacaterol—Dizziness—Vincristine—lymphatic system cancer	0.0011	0.00361	CcSEcCtD
Indacaterol—Rash—Carmustine—lymphatic system cancer	0.0011	0.0036	CcSEcCtD
Indacaterol—Dermatitis—Carmustine—lymphatic system cancer	0.0011	0.0036	CcSEcCtD
Indacaterol—Headache—Carmustine—lymphatic system cancer	0.0011	0.00358	CcSEcCtD
Indacaterol—Cardiac disorder—Methotrexate—lymphatic system cancer	0.00106	0.00346	CcSEcCtD
Indacaterol—Rash—Vincristine—lymphatic system cancer	0.00105	0.00344	CcSEcCtD
Indacaterol—Dermatitis—Vincristine—lymphatic system cancer	0.00105	0.00344	CcSEcCtD
Indacaterol—Headache—Vincristine—lymphatic system cancer	0.00105	0.00342	CcSEcCtD
Indacaterol—Nausea—Carmustine—lymphatic system cancer	0.00104	0.00339	CcSEcCtD
Indacaterol—Immune system disorder—Methotrexate—lymphatic system cancer	0.00103	0.00336	CcSEcCtD
Indacaterol—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.00103	0.00336	CcSEcCtD
Indacaterol—Rash—Mitoxantrone—lymphatic system cancer	0.00103	0.00335	CcSEcCtD
Indacaterol—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00102	0.00335	CcSEcCtD
Indacaterol—Headache—Mitoxantrone—lymphatic system cancer	0.00102	0.00333	CcSEcCtD
Indacaterol—Malnutrition—Methotrexate—lymphatic system cancer	0.000993	0.00324	CcSEcCtD
Indacaterol—Nausea—Vincristine—lymphatic system cancer	0.000992	0.00324	CcSEcCtD
Indacaterol—Nausea—Mitoxantrone—lymphatic system cancer	0.000966	0.00315	CcSEcCtD
Indacaterol—Anaemia—Methotrexate—lymphatic system cancer	0.000918	0.003	CcSEcCtD
Indacaterol—Vertigo—Methotrexate—lymphatic system cancer	0.000892	0.00291	CcSEcCtD
Indacaterol—Cough—Methotrexate—lymphatic system cancer	0.000866	0.00283	CcSEcCtD
Indacaterol—Chest pain—Methotrexate—lymphatic system cancer	0.000845	0.00276	CcSEcCtD
Indacaterol—Myalgia—Methotrexate—lymphatic system cancer	0.000845	0.00276	CcSEcCtD
Indacaterol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000839	0.00274	CcSEcCtD
Indacaterol—Infection—Methotrexate—lymphatic system cancer	0.000805	0.00263	CcSEcCtD
Indacaterol—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000795	0.00259	CcSEcCtD
Indacaterol—Skin disorder—Methotrexate—lymphatic system cancer	0.000787	0.00257	CcSEcCtD
Indacaterol—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000738	0.00241	CcSEcCtD
Indacaterol—Paraesthesia—Methotrexate—lymphatic system cancer	0.000728	0.00238	CcSEcCtD
Indacaterol—Dyspnoea—Methotrexate—lymphatic system cancer	0.000722	0.00236	CcSEcCtD
Indacaterol—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.0007	0.00228	CcSEcCtD
Indacaterol—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000597	0.00195	CcSEcCtD
Indacaterol—Pruritus—Methotrexate—lymphatic system cancer	0.000573	0.00187	CcSEcCtD
Indacaterol—Dizziness—Methotrexate—lymphatic system cancer	0.000536	0.00175	CcSEcCtD
Indacaterol—Rash—Methotrexate—lymphatic system cancer	0.000511	0.00167	CcSEcCtD
Indacaterol—Dermatitis—Methotrexate—lymphatic system cancer	0.00051	0.00167	CcSEcCtD
Indacaterol—Headache—Methotrexate—lymphatic system cancer	0.000508	0.00166	CcSEcCtD
Indacaterol—Nausea—Methotrexate—lymphatic system cancer	0.000481	0.00157	CcSEcCtD
